Viking Therapeutics (VKTX) initiated an exploratory maintenance dosing study of VK2735, the company’s dual agonist of the glucagon-like peptide 1 – GLP-1 – and glucose-dependent insulinotropic polypeptide – GIP – receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. The trial is intended to explore the feasibility of various VK2735 maintenance dosing regimens utilizing either the oral tablet or the subcutaneous formulation to sustain the initial weight loss achieved following weekly subcutaneous dosing. The objectives of the study are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Options Volatility and Implied Earnings Moves This Week, October 20 – October 24, 2025
- Is VKTX a Buy, Before Earnings?
- Viking Therapeutics: Promising Position in GLP-1 Market with Strategic Growth Potential
- Viking Therapeutics: Strong Buy Rating Amid Strategic Positioning and Acquisition Potential in the Metabolic Disease Market
- Pfizer’s Metsera deal provides positive readthrough to Viking, says BTIG